Company news

Lantheus Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

March 26, 2023

Lantheus Announces Two Key Executive Promotions

March 16, 2023

Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

February 15, 2023

Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8: 00 a.m. Eastern Time

February 8, 2023

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

February 7, 2023

Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease

February 5, 2023

Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference

January 3, 2023

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

December 19, 2022

Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform

December 11, 2022

Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027

December 5, 2022

Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027

December 4, 2022

Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

November 28, 2022

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

November 27, 2022

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

November 13, 2022

Lantheus Reports Third Quarter 2022 Financial Results

November 2, 2022

Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8: 00 a.m. Eastern Time

October 19, 2022

Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data

October 16, 2022

GE Healthcare and Lantheus Phase III Clinical Trial Finds [¹⁸F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

September 12, 2022

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

September 12, 2022

Lantheus Reports Second Quarter 2022 Financial Results

August 3, 2022

Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8: 00 a.m. Eastern Time

July 20, 2022

Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer

June 14, 2022

Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer

June 12, 2022

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

June 12, 2022

Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

May 25, 2022

Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting

May 15, 2022

Lantheus Hosts Inaugural Investor Day

May 15, 2022

Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients

May 12, 2022

Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer

May 10, 2022

Lantheus to Present at the UBS Global Healthcare Conference

May 9, 2022

Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results

April 28, 2022

Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8: 00 a.m. Eastern Time

April 14, 2022

Lantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer

April 3, 2022

Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development

March 28, 2022

Lantheus Holdings to Present at the Barclays Global Healthcare Conference

March 7, 2022

Lantheus to Host Inaugural Investor Day

March 2, 2022

Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

February 28, 2022

Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Lantheus Receives U.S. FDA Approval of New Manufacturing Facility

February 22, 2022

Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8: 00 a.m. Eastern Time

February 9, 2022

Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting

February 9, 2022

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

January 26, 2022

Lantheus Appoints Vivian Yao as Chief Human Resources Officer

November 30, 2021

Lantheus Announces PYLARIFY AI™ is Now Available

November 28, 2021

Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022

November 21, 2021

Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings

November 16, 2021

Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 15, 2021

Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results

November 3, 2021

Lantheus Holdings to Present at Upcoming Investor Conferences

October 27, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.